Gene therapy reduces bleeding rates and factor use in adults with severe hemophilia A
Can gene therapy reduce bleeding and treatment burden for adults with severe hemophilia A?
A systematic review and meta-analysis of adults with severe/moderately severe hemophilia A found gene therapy reduced annualized bleeding ra…
For adults with severe hemophilia A, gene therapy may offer a way to bleed less and rely far less on regular infusions. A review of existing…
Concizumab Reduces Bleeding in Hemophilia with Inhibitors: Median ABR 0.8 at 56 Weeks
Could a New Treatment Change the Lives of People with Hemophilia?
In the phase 3 explorer7 RCT, concizumab prophylaxis significantly reduced median annualized bleeding rate (ABR) to 0.8 in patients with hem…
A new treatment for hemophilia helped patients with inhibitors experience just one bleeding episode a year, offering hope for fewer interrup…